BI-4464 is primarily used in the field of cancer research, particularly in the study of acute myeloid leukemia (AML) and other hematologic malignancies. It functions as a potent and selective inhibitor of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1), which is often mutated in certain cancers. By targeting this mutation, BI-4464 helps to inhibit the production of the oncometabolite 2-hydroxyglutarate (2-HG), which drives cancer progression. This makes it a valuable tool for understanding the role of IDH1 mutations in tumorigenesis and for developing targeted therapies. Additionally, it is utilized in preclinical studies to evaluate its efficacy and safety as a potential therapeutic agent for IDH1-mutated cancers.